AI-native biotech Earendil Labs secured $787 million in private funding to accelerate a large pipeline of biologics across autoimmune and oncology programs and to expand R&D operations in the U.S. and China. The round, led by Dimension and Luminous Ventures with Sanofi participation, funds multiple programs toward clinical testing and supports a potential Hong Kong IPO. CEO Jian Peng said the capital lets the company operate at a “fundamentally different scale.” Earendil is developing >40 programs—including bispecifics, T-cell engagers and antibody‑drug conjugates—focused on targets like DLL3 (lung cancer) and TL1A (IBD). The company’s strategy combines AI design with rapid experimental validation and has drawn repeat partnerships with Sanofi. Investors and industry watchers view the financing as a signal that large private financings for AI-driven biotech remain available for firms showing rapid translational execution.